Please assess the completion status of the following clinical trial:

Trial Title: Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically documented invasive epithelial ovarian carcinoma, cancer of the fallopian tube or the peritoneum refractory to platinum-based chemotherapy or with partially platinum sensitive disease.~* Planned therapy with pegylated liposomal doxorubicin 50 mg/m² for recurrent platinum-refractory ovarian cancer.~* Patients with a progression-free-interval of 6 to 12 months after platinum-based chemotherapy are only eligible if a further course of platinum-based combination chemotherapy is not possible as judged by the investigator(s).~* Patients must have received at least one previous platinum- and taxane-based chemotherapy regimen.~Exclusion Criteria:~* Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days~* Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function~* Treatment with mouse-antibodies in patients with evaluable disease and CA-125 progressive disease in the last 3 months. These patients are only eligible in case of measurable disease according to RECIST or cytological/histological proven relapse~* More than two prior lines of chemotherapy.~* Any chemotherapy or other systemic anti-cancer therapy within four weeks prior to randomization.~* Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Vandetanib added to standard therapy (pegliposomal doxorubicin)

Based on this trial design, predict the completion outcome and termination type (if applicable).